Zinc metabolism during captopril treatment.
In 14 hypertensives the effect of captopril (angiotensin-converting enzyme inhibitor) treatment on red blood cell Na+, K+, Mg2+ and Zn2+ concentrations and on plasma Zn2+ concentrations were studied. Intraerythrocytic Zn2+ concentrations increased slightly, whereas plasma zinc concentrations decreased. The concurrence of hypozincemia with side effects resembling the symptoms of zinc deficiency such as loss of smell and taste suggests a role of alterations in zinc metabolism for the pharmacodynamics of captopril.
D000328:Adult; D002216:Captopril / Q000627:therapeutic use*; D004912:Erythrocytes / Q000032:analysis; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011392:Proline / Q000031:analogs & derivatives*; D012964:Sodium / Q000097:blood; D015032:Zinc / Q000097:blood*
D011392:Proline; D002216:Captopril; D012964:Sodium; D008274:Magnesium; D015032:Zinc; D011188:Potassium